This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuji, M.
Right arrow Articles by Kuwahara, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuji, M.
Right arrow Articles by Kuwahara, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2507-2512, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2507-2512.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vivo Antibacterial Activity of S-3578, a New Broad-Spectrum Cephalosporin: Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Experimental Infection Models

Masakatsu Tsuji,1* Morio Takema,1 Hideaki Miwa,1 Jingoro Shimada,2 and Shogo Kuwahara3

Discovery Research Laboratories, Shionogi Co., Ltd., Toyonaka, Osaka 561-0825,1 St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511,2 Toho University School of Medicine, Ota-ku, Tokyo 143-8540, Japan3

Received 30 August 2002/ Returned for modification 19 February 2003/ Accepted 10 May 2003

The in vivo antibacterial activity of S-3578, a new parental cephalosporin, was compared with those of cefepime, ceftriaxone, ceftazidime, imipenem-cilastatin, and vancomycin. The efficacy of S-3578 against systemic infections caused by methicillin-resistant Staphylococcus aureus (MRSA) SR3637 (50% effective dose [ED50], 7.21 mg/kg of body weight) was almost the same as that of vancomycin. In contrast, cefepime and imipenem-cilastatin were less active against this pathogen (ED50s, >100 and >100 mg/kg, respectively). S-3578 was the most effective compound against penicillin-resistant Streptococcus pneumoniae SR20946 (ED50, 1.98 mg/kg). S-3578 (10 mg/kg) induced a significant reduction in the numbers of viable MRSA SR17764 and Pseudomonas aeruginosa SR10396 organisms in polymicrobial pulmonary infections. The therapeutic efficacy of S-3578 was more potent than that of the combination of vancomycin and ceftazidime. High levels of S-3578 were detected in plasma in vivo, and its efficacy against experimentally induced infections in mice caused by MRSA and P. aeruginosa reflected its potent in vitro activity. We conclude that S-3578 is a promising new cephalosporin for the treatment of infections caused by gram-positive and -negative bacteria, including MRSA and P. aeruginosa.

* Corresponding author. Mailing address: Discovery Research Laboratories, Shionogi Co., Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan. Phone: 81 (6) 6331-8081. Fax: 81 (6) 6331-8612. E-mail: masakatsu.tsuji{at}shionogi.co.jp.

Antimicrobial Agents and Chemotherapy, August 2003, p. 2507-2512, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2507-2512.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Jacqueline, C., Caillon, J., Le Mabecque, V., Miegeville, A.-F., Hamel, A., Bugnon, D., Ge, J. Y., Potel, G. (2007). In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model. Antimicrob. Agents Chemother. 51: 3397-3400 [Abstract] [Full Text]  
  • Ueda, Y., Kanazawa, K., Eguchi, K., Takemoto, K., Eriguchi, Y., Sunagawa, M. (2005). In Vitro and In Vivo Antibacterial Activities of SM-216601, a New Broad-Spectrum Parenteral Carbapenem. Antimicrob. Agents Chemother. 49: 4185-4196 [Abstract] [Full Text]  
  • Huang, V., Brown, W. J., Rybak, M. J. (2004). In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci. Antimicrob. Agents Chemother. 48: 2719-2723 [Abstract] [Full Text]  
  • Miyazaki, S., Okazaki, K., Tsuji, M., Yamaguchi, K. (2004). Pharmacodynamics of S-3578, a Novel Cephem, in Murine Lung and Systemic Infection Models. Antimicrob. Agents Chemother. 48: 378-383 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»